Tag Archives: Testing

NIHR Signal – MRI scans help confirm ultrasound diagnosis of fetal brain abnormalities

Cava septum pellucidi
Image Source: WikiMedia Commons

If fetal brain abnormality is suspected on a pregnancy ultrasound, following this with in-utero MRI (iuMRI) improves diagnostic accuracy. This sequence could allow more informed discussions and decision-making around whether to continue with or terminate a pregnancy.

The NIHR funded study included 565 women of 18 weeks’ pregnancy or more who received ultrasound followed by iuMRI. Diagnoses were confirmed either by postnatal imaging of the baby or at post-mortem examination.

Overall iuMRI gave the correct diagnosis for 93% of scans compared to only 68% of ultrasounds. The accuracy of ultrasound declined above 24 weeks of pregnancy, whereas iuMRI performed well at all times. Clinicians reported that iuMRI scan results caused them to modify their future care planning in over 20% of cases.

Cost effectiveness was not assessed and iuMRI scans are not as widely available as ultrasound. Therefore, resource issues are an important consideration when judging whether or how to implement iuMRI into the diagnostic pathway.

Read the full signal here

Advertisements

Zika in pregnancy research shows fetal anomaly rates

Original Title: AA_0099sRGB.tif
Image Source: Public Health Image Library (PHIL) via Flickr

New research published in JAMA has attempted to answer the question  of  what proportion of fetuses and infants of women in the United States with laboratory evidence of possible Zika virus infection during pregnancy have birth defects.

“Conclusions and Relevance: Among pregnant women in the United States with completed pregnancies and laboratory evidence of possible recent Zika infection, 6% of fetuses or infants had evidence of Zika-associated birth defects, primarily brain abnormalities and microcephaly, whereas among women with first-trimester Zika infection, 11% of fetuses or infants had evidence of Zika-associated birth defects. These findings support the importance of screening pregnant women for Zika virus exposure”

Source: Honein MA, Dawson AL, Petersen EE et al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy JAMA. 2017 Jan 3;317(1):59-68

Read the full article here

Full implementation of newborn blood spot failsafe system is great news for all babies born in England

nhs_uclh-maternity-newborn-47-11490
Image Source: NHS Photolibrary

The Newborn Blood Spot Failsafe Solution (NBSFS) IT system, which flags up babies who may have missed screening, is now complete in all parts of England.  The NHS Newborn Blood Spot (NBS) Screening Programme uses a heel prick test to screen newborn babies for 9 rare but serious conditions. Babies who test positive can then be treated early, improving their health and, in some cases, preventing severe disability or even death.  For some time, the system has been able to identify babies who have had no NBS screening at all, but until now it couldn’t always track babies who needed a repeat test.

Link to Public Health England Blood Spot Screening Programme here

 

Screening newborns for muscle wasting condition not recommended

nhs_uclh-maternity-newborn-47-11490
Photo source: NHS Photo Library

PHE Press release: Screening newborns for muscle wasting condition not recommended
Newborn babies should not be screened for the muscle wasting condition Duchenne Muscular Dystrophy, according to the UK’s independent expert screening committee.
The current test available for the condition incorrectly identifies some babies as having the condition and misses others who go on to develop the disease

Link to press release here

High-throughput non-invasive prenatal testing for fetal RHD genotype

 

427bab-8543
Image Source:  NHS Photo Library

NICE Diagnostics Guidance 25 

High-throughput non-invasive prenatal testing for fetal RHD genotype | 1-Recommendations | Guidance and guidelines | NICE

1 Recommendations

1.1 High-throughput non‑invasive prenatal testing (NIPT) for fetal RHD genotype is recommended as a cost-effective option to guide antenatal prophylaxis with anti‑D immunoglobulin, provided that the overall cost of testing is £24 or less. This will help reduce unnecessary use of a blood product in pregnant women, and conserve supplies by only using anti‑D immunoglobulin for those who need it.

1.2 Cost savings associated with high-throughput NIPT for fetal RHD genotype are sensitive to the unit cost of the test, additional pathway costs and implementation costs. Trusts adopting NIPT should collect and monitor the costs and resource use associated with implementing testing to ensure that cost savings are achieved (see section 6.1).